Initial Claims More Than Expectations
For months, we've been talking in this space about the steadiness and resiliency of weekly unemployment claims. While other metrics on the economy and employment have begun to show some volatility of late, these Thursday morning releases have for the most part kept a ceiling of 225K on near-term claims and sub-1.9 million on longer-term claims. That changes this morning, on both counts.Last week, 241K Americans filed for unemployment on Initial Jobless Claims, well north of the 225K analysts were expecting and slightly upwardly revised 223K for the previous week. This level north of 240K was last reached back in the third week of February this year, which stands as an outlier relative to weeks on either side. Perhaps that will be the case here, as well. Future weeks will let us know.Continuing Claims breached 1.9 million for the first time in several weeks: 1.916 million were filed two weeks ago (longer-term claims report a week in arrears from new claims), the highest level (for now) since November 2021. But we have been here before: previous weeks this year have initially sounded the 1.9 million gong, only to revised it back down to the high 1.8 million level the following week. Again, we need to wait to see in future weeks whether this gets taken back below that threshold or start developing signs of labor market weakness.
Big Pharma staple Eli Lilly LLY posted mixed results ahead of today's open, missing on earnings — $3.34 per share versus $3.52 expected, for a negative surprise of -5% — while beating on revenues: $12.73 billion, +0.8% from projections and well ahead of last year's $8.77 billion reported. Sales on weight-loss drug Mounjaro surged to $3.84 billion in the quarter. However, while forward revenue guidance was kept intact, LLY shares are down -4.7% on the news this morning.McDonald's MCD was also mixed in its Q1 report ahead of today's open, with earnings of $2.67 per share advancing past the Zacks consensus by 3 cents on revenues of $5.96 billion, which missed expectations by -2.12%. Same-store sales fell to their lowest levels in 5 years (the dreaded 'Covid era') and shares had been down -2% on the news. This cuts into the company's +10% gains year to date.CVS Health CVS, which has re-prioritized its business away from expensive brick-and-mortar shops, posted a big Q1 earnings beat this morning: $2.25 per share versus $1.71 anticipated, for a +31.6% quarterly beat. Revenues of $94.59 billion in the period outpaced estimates by +1.76%. CVS is quietly one of the big success stories in 2025: shares are up another +8.7% at this hour, adding to its +48% gains year to date.Perhaps no company this morning posted a bigger upside surprise than home goods supply firm Wayfair W, which swung to a positive +$0.10 per share on earnings from -$0.18 expected, for a surprise of +155%. Revenues of $2.73 billion for the quarter was +0.70% ahead of estimates, and exactly in-line with the previous month. Shares are up +6% in early trading; it still has a ways to go before it makes back the -32% in losses, year to date. For more on W's earnings, click here.
Once regular trading opens for business this morning, we'll await the final print on S&P Manufacturing PMI and ISM Manufacturing, both for April. The S&P print looks to dial back narrowly to 50.6 — importantly, still above the 50-threshold that determines gain from loss. ISM Manufacturing, however, is expected to recess deeper into that sub-50 mire: 47.8% in the consensus estimate; 49.0% was the headline last time around.Construction Spending results for March will also be in the offing a little later this morning. These are expected to drop half a percentage point month over month — from +0.7% for February to +0.2% the following month. These data sets look into the past a bit; we expect metrics like these to experience bigger changes as current trade policy in the U.S. comes under heavier consideration.After today's closing bell, we'll hear from Amazon AMZN and — a half-hour after the normal session ends — Apple AAPL on Q1 earnings results. These are the two 'Mag 7' stocks we referred to earlier. Elsewhere, this afternoon also brings us Mastercard MA, Amgen AMGN and Twilio TWLO earnings after the bell, among many others.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Amazon.com, Inc. (AMZN) : Free Stock Analysis Report
Apple Inc. (AAPL) : Free Stock Analysis Report
Mastercard Incorporated (MA) : Free Stock Analysis Report
Eli Lilly and Company (LLY) : Free Stock Analysis Report
Amgen Inc. (AMGN) : Free Stock Analysis Report
McDonald's Corporation (MCD) : Free Stock Analysis Report
CVS Health Corporation (CVS) : Free Stock Analysis Report
Wayfair Inc. (W) : Free Stock Analysis Report
Twilio Inc. (TWLO) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
Eli Lilly and Company (LLY) Releases Q2 2025 Results
Eli Lilly and Company (NYSE:LLY) is one of the Reddit Stocks with the Highest Upside Potential. On August 7, the company released Q2 2025 results, with revenues increasing 38% to $15.56 billion, thanks to the volume growth from Zepbound and Mounjaro. Furthermore, Eli Lilly and Company (NYSE:LLY) raised the midpoint of its 2025 full-year revenue guidance by $1.5 billion to be between $60 billion – $62 billion. The company expects reported EPS to be between $20.85 – $22.10, and non-GAAP EPS of between $21.75 – $23.00. Eli Lilly and Company (NYSE:LLY)'s pipeline has been advancing, thanks to positive study results in oncology and cardiometabolic health, such as Mounjaro's demonstrated cardio-protective effects in patients with type 2 diabetes and heart disease and healthy data for its oral incretin, orforglipron, in obesity. Eli Lilly and Company (NYSE:LLY) also expanded manufacturing capacity in a bid to meet elevated demand and invested in critical R&D initiatives to support its long-term growth. In Q2 2025, R&D expenses rose 23% to $3.34 billion, or 21.4% of revenue. This was because of continued investments in its early and late-stage portfolio. Impax Asset Management, an investment management company, released its Q2 2025 investor letter. Here is what the fund said: 'Eli Lilly and Company (NYSE:LLY) (Health Care, Pharmaceuticals) boasts an innovative drug portfolio that has the potential to transform the standard of care across several diseases. The stock was weaker in the quarter despite results that were in-line or better than expectations. Shares were under pressure after CVS' announcement that competitor Novo Nordisk's Wegovy will now be the preferred GLP-1 drug on their national formulary, which currently represents a mid-single digit percentage of Lilly's current Zepbound patients.' While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Miami Herald
4 hours ago
- Miami Herald
Starbucks rival continues its US expansion
Whether you're a coffee lover or not, Starbucks is nearly impossible to ignore. With over 40,000 locations in 80 countries, it has become the most recognizable name in coffee worldwide; chances are, almost everyone has tried something from its menu at least once. However, Starbucks has experienced a noticeable decline in recent years. Sales are down, store traffic has slowed, and concerns about the company's long-term growth have prompted a major turnaround strategy to revive its business. Don't miss the move: Subscribe to TheStreet's free daily newsletter While Starbucks still dominates the market, smaller chains like Dutch Bros (BROS) , Scooter's Coffee, and 7 Brew Coffee have been gaining traction, steadily growing their customer bases. Now, Starbucks faces perhaps its most significant challenge yet. A powerful international rival has entered the U.S. market, threatening its position as a coffee leader. Related: Starbucks faces huge new rival Founded in 2017 in Beijing, Luckin Coffee (LKNCY) entered the coffee scene 46 years after Starbucks (SBUX) launched, and has already surpassed expectations. With over 22,000 stores, it's now the largest coffee chain in China, overshadowing Starbucks in that market. Although relatively unknown to Americans, Luckin Coffee immediately caught people's attention when it opened its first stores in New York City on June 30. It debuted two locations, one at 55 Broadway and another at 800 6th Ave., introducing its blue-and-white deer logo to the U.S. Image source:Luckin Coffee is known for its high-quality coffee and wide range of menu options at affordable prices. However, due to economic and currency differences, prices at its U.S. locations are understandably higher than in Asia. Starbucks has faced backlash over the last few months for raising its prices. In response to criticism, it simplified its menu and eliminated extra charges, a timely move that coincides with its rival's arrival in the U.S. Related: Starbucks' huge new rival opens first US stores When comparing their menus, Luckin Coffee clearly acknowledges Starbucks as a competitor. Both chains carry handcrafted coffee beverages, frappes, matcha drinks, and refreshers. Their prices are also very similar, with a 16-ounce drip coffee costing $3.45. And so far, U.S. consumers seem intrigued to give Luckin Coffee a chance. During its opening week, lines were out the door, with many people eager to try the new coffee shop in town. Keeping the momentum, Luckin Coffee has wasted no time expanding into the U.S. In a recent Instagram post, the company teased the grand opening of its third location in New York City, hinting that the new store will be "steps away from Columbus Circle" and asking people to guess the exact location. This sparked a wave of fans quickly flooding the comments section, with many commenting "901 8th Ave." More Food News: After bankruptcy, Starbucks rival plans aggressive expansionPizza Hut menu adds a completely new type of pizzaHershey teams up with Costco to make a dream candy combo The Chinese coffee chain also posted a picture to its Instagram story revealing the outside of the new coffee shop, which appears completed. Although Luckin Coffee has yet to provide an official date for the grand opening of its new location, it claims it will be opening very soon. To promote it, Luckin Coffee launched a scavenger hunt that will end on August 18 and allows participants to win prizes and free drinks. This suggests that the third store could open on Monday Aug. 18. Related: Starbucks plans major change to how it adds new menu items The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.

Wall Street Journal
6 hours ago
- Wall Street Journal
Americans Pull Back From an Epic Credit-Card Binge
Americans are starting to pull back from a pandemic-era credit-card binge. After a surge in credit-card spending that pushed Americans' card balances above $1 trillion, growth is now moderating. Credit-card spending has been growing more slowly than debit-card spending since late last year, the first such stretch in nearly four years, according to the latest spending data from Visa and Mastercard.